MapLight's schizophrenia drug fails once-daily test, shares plunge

July 27th, 2026 | 12:30 PM BUSINESS Healthcare & Pharmaceuticals 1

Facebook Twitter Google+ LinkedIn Pinterest
By Reuters

MapLight Therapeutics (MPLT.O) said on Monday its schizophrenia drug failed to show statistically significant symptom improvement in the once-daily dosing arm of ​a mid-stage trial, sending its shares tumbling 55% in ‌premarket trading.

Here are the details:

Related Posts

© Financetime.org 2026. All rights reserved. Hosted by LeadsDeposit.com
Produced by C-iT